These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

932 related articles for article (PubMed ID: 23828580)

  • 1. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD007545. PubMed ID: 23828580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Evid Based Child Health; 2014 Mar; 9(1):169-294. PubMed ID: 25404581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
    Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Six-month therapy for abdominal tuberculosis.
    Jullien S; Jain S; Ryan H; Ahuja V
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012163. PubMed ID: 27801499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent versus daily therapy for treating tuberculosis in children.
    Bose A; Kalita S; Rose W; Tharyan P
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD007953. PubMed ID: 24470141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: a systematic review.
    Hamada Y; Ford N; Schenkel K; Getahun H
    Int J Tuberc Lung Dis; 2018 Dec; 22(12):1422-1428. PubMed ID: 30606313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis.
    Gallardo CR; Rigau Comas D; Valderrama Rodríguez A; Roqué i Figuls M; Parker LA; Caylà J; Bonfill Cosp X
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD009913. PubMed ID: 27186634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifabutin for treating pulmonary tuberculosis.
    Davies G; Cerri S; Richeldi L
    Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD005159. PubMed ID: 17943842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of latent tuberculosis infection in HIV infected persons.
    Akolo C; Adetifa I; Shepperd S; Volmink J
    Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD000171. PubMed ID: 20091503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interventions for the treatment of metastatic extradural spinal cord compression in adults.
    George R; Jeba J; Ramkumar G; Chacko AG; Tharyan P
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD006716. PubMed ID: 26337716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses.
    Pease C; Hutton B; Yazdi F; Wolfe D; Hamel C; Quach P; Skidmore B; Moher D; Alvarez GG
    BMC Infect Dis; 2017 Apr; 17(1):265. PubMed ID: 28399802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Directly observed therapy for treating tuberculosis.
    Karumbi J; Garner P
    Cochrane Database Syst Rev; 2015 May; 2015(5):CD003343. PubMed ID: 26022367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linezolid for drug-resistant pulmonary tuberculosis.
    Singh B; Cocker D; Ryan H; Sloan DJ
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012836. PubMed ID: 30893466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study.
    Surey J; Stagg HR; Yates TA; Lipman M; White PJ; Charlett A; Muñoz L; Gosce L; Rangaka MX; Francis M; Hack V; Kunst H; Abubakar I
    BMC Infect Dis; 2021 Jan; 21(1):90. PubMed ID: 33478428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax.
    Milligan R; Daher A; Villanueva G; Bergman H; Graves PM
    Cochrane Database Syst Rev; 2020 Aug; 8():CD012656. PubMed ID: 32816320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reminder systems to improve patient adherence to tuberculosis clinic appointments for diagnosis and treatment.
    Liu Q; Abba K; Alejandria MM; Sinclair D; Balanag VM; Lansang MA
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD006594. PubMed ID: 25403701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of latent tuberculosis infection: An update.
    Lobue P; Menzies D
    Respirology; 2010 May; 15(4):603-22. PubMed ID: 20409026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine.
    Galappaththy GN; Tharyan P; Kirubakaran R
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD004389. PubMed ID: 24163057
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 47.